These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2534279)

  • 1. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
    Smith EF
    Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of thromboxane receptor antagonists in cardiovascular disease.
    Smith EF
    Prog Clin Biol Res; 1989; 301():29-38. PubMed ID: 2529549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
    Fiddler GI; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition.
    Patscheke H; Hornberger W; Zehender H
    Z Kardiol; 1990; 79 Suppl 3():151-4. PubMed ID: 2099038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of thromboxane A2 receptor antagonists.
    Halushka PV
    Z Kardiol; 1989; 78 Suppl 3():42-7. PubMed ID: 2530712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
    Halushka PV; Mais DE; Saussy DL
    Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
    Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thromboxane antagonism in thrombocytes--pathophysiology, pharmacology and possible clinical significance].
    Schrör K
    Wien Klin Wochenschr; 1991; 103(18):543-53. PubMed ID: 1836294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
    Sakariassen KS; Alberts P; Fontana P; Mann J; Bounameaux H; Sorensen AS
    Future Cardiol; 2009 Sep; 5(5):479-93. PubMed ID: 19715412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
    Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
    Radomski M
    Acta Physiol Pol; 1985; 36(3):153-64. PubMed ID: 3915630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists].
    Kohno S
    Nihon Rinsho; 1996 Feb; 54(2):551-8. PubMed ID: 8838113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thromboxane A2 and prevention of cardiovascular diseases].
    Schrör K
    Z Kardiol; 1992; 81 Suppl 4():185-9. PubMed ID: 1290297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
    Fitzgerald DJ; Fragetta J; FitzGerald GA
    J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.